These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 16582692)

  • 21. Clinical value of blocking IL-6 receptor.
    Mima T; Nishimoto N
    Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of anti-cytokines and anti-RANKL antibody for treatment of RA and osteoporosis].
    Okada Y; Nawata M; Tanaka Y
    Clin Calcium; 2007 Nov; 17(11):1762-8. PubMed ID: 17982198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical safety of tocilizumab in rheumatoid arthritis.
    Bannwarth B; Richez C
    Expert Opin Drug Saf; 2011 Jan; 10(1):123-31. PubMed ID: 21121872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
    Nasonov EL
    Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tocilizumab for rheumatoid arthritis.
    Drug Ther Bull; 2010 Jan; 48(1):9-12. PubMed ID: 20040568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Tocilizumab in rheumatoid arthritis. Interleukin 6 as a new target].
    Heinzl S
    Med Monatsschr Pharm; 2008 Dec; 31(12):450-3. PubMed ID: 19133593
    [No Abstract]   [Full Text] [Related]  

  • 27. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ; Hyrich KL
    BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentiating the efficacy of tumor necrosis factor inhibitors.
    Haraoui B
    J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-6 inhibition--tolerability profile and clinical implications.
    Strand V; Yazici Y
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S21-4. PubMed ID: 17708741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
    Woodrick RS; Ruderman EM
    Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-interleukin 6: first line in rheumatoid arthritis?
    Marti L; Scheinberg M
    Clin Rheumatol; 2009 Aug; 28(8):877-9. PubMed ID: 19415377
    [No Abstract]   [Full Text] [Related]  

  • 32. [Proposal for biologic drugs therapy in rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S; Kaliterna DM; Hanih M; Novak S
    Reumatizam; 2010; 57(1):29-35. PubMed ID: 20941938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biochemical markers of bone turnover. New aspect. Therapy of rheumatoid arthritis for bone metabolic marker].
    Okada Y; Nawata M; Tanaka Y
    Clin Calcium; 2009 Aug; 19(8):1186-90. PubMed ID: 19638703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rheumatoid polyarthritis: a new treatment].
    Perspect Infirm; 2010; 7(5):46-7. PubMed ID: 21744636
    [No Abstract]   [Full Text] [Related]  

  • 37. [IL-6: the next key target for rheumatoid arthritis after TNF-α].
    Li Y; Zhang W
    Sheng Wu Gong Cheng Xue Bao; 2017 Jan; 33(1):36-43. PubMed ID: 28959861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The efficacy of the three available anti-tumour necrosis factor therapies in patients with rheumatoid arthritis. A meta-analytic literature review--secondary publication].
    Christensen R; Kristensen LE; Geborek P; Danneskiold-Samsøe B; Saxne T; Bliddal H
    Ugeskr Laeger; 2009 Jun; 171(26):2192-4. PubMed ID: 19678436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rheumatoid arthritis: Biological therapy other than anti-TNF.
    Rossi D; Modena V; Sciascia S; Roccatello D
    Int Immunopharmacol; 2015 Aug; 27(2):185-8. PubMed ID: 25840282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential.
    Liu X; Li L; Wang Q; Jiang F; Zhang P; Guo F; Liu H; Huang J
    Front Immunol; 2021; 12():816646. PubMed ID: 35126375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.